Related Experiment Video
Updated: Aug 8, 2026

Colon Ascendens Stent Peritonitis (CASP) - a Standardized Model for Polymicrobial Abdominal Sepsis
Published on: December 19, 2010
Impaired cell-mediated immunity in experimental abdominal sepsis and the effect of interleukin 2
D B Gough1, A Jordan, J A Mannick
1Department of Surgery, Brigham and Women's Hospital-Harvard Medical School, Boston, MA 02115.
Insights
Sepsis temporarily impairs cell-mediated immunity, with responses initially enhanced then suppressed. Interleukin 2 (IL-2) treatment restored immune responses in vitro and improved survival in vivo, suggesting IL-2
Area of Science:
- Immunology
- Sepsis Research
- Infectious Disease
Background:
- Experimental sepsis models are crucial for understanding infection's impact on immunity.
- Cell-mediated immunity plays a key role in host defense against pathogens.
- Interleukin 2 (IL-2) is a critical cytokine for immune cell function.
Purpose of the Study:
- To investigate the effects of experimental sepsis on in vitro cell-mediated immunity in a murine model.
- To evaluate the role of in vitro and in vivo interleukin 2 (IL-2) in modulating immune responses and survival during sepsis.
Main Methods:
- Cecal ligation and puncture (CLP) was used to induce sepsis in mice.
- Splenocyte responses to mitogens (phytohemagglutinin and concanavalin A) were measured in vitro.
- The impact of in vitro and in vivo IL-2 administration on immune responses and survival was assessed.
Main Results:
- Sepsis initially enhanced, then suppressed, splenocyte responses to mitogens.
- In vitro IL-2 restored suppressed phytohemagglutinin responses.
- In vivo IL-2 treatment improved survival rates in septic mice after the initial phase.
Conclusions:
- Sepsis causes a transient impairment of cell-mediated immunity.
- Interleukin 2 demonstrates potential therapeutic value in mitigating sepsis-induced immune dysfunction and improving outcomes.
Abstract:
A murine model of experimental sepsis, ie, cecal ligation and puncture, was used to determine the potential effects of infection on in vitro cell-mediated immunity. Following cecal ligation and puncture, in vitro responses of mouse splenocytes to mitogens (phytohemagglutinin and concanavalin A), the effects of in vitro interleukin 2 on these responses, and the impact of in vivo interleukin 2 on survival were studied. Compared with controls (sham cecal ligation and puncture), phytohemagglutinin responses 1 day after cecal ligation and puncture were enhanced (43% +/- 17%, n = 9), phytohemagglutinin and concanavalin A responses at day 4 were suppressed (45.5% +/- 4.4% and 57.5% +/- 5.6%), and, by day 7, phytohemagglutinin and concanavalin A responses were approaching values in mice treated by sham cecal ligation and puncture. Suppressed phytohemagglutinin responses at day 4 after cecal ligation and puncture were restored to normal with in vitro interleukin 2 (61,052 +/- 3407 cpm for cecal ligation and puncture and 64,643 +/- 4727 cpm for sham cecal ligation and puncture). Mortalities following cecal ligation and puncture were identical at day 1 after cecal ligation and puncture (6/20) for both interleukin 2- and vehicle-treated groups; thereafter, interleukin 2-treated groups fared better. At day 1 after cecal ligation and puncture, the mean spleen cell phytohemagglutinin response was enhanced (43.8% +/- 17%, n = 9) compared with sham cecal ligation and puncture (= 10). By day 4, the responses to both concanavalin A and phytohemagglutinin were suppressed (45.5% +/- 4.4% and 57.5% +/- 5.6%, respectively). Responses at day 7 approached those of controls given sham cecal ligation and puncture. Sepsis causing a temporary impairment of cell-mediated immunity may be a factor in the frequent coexistence of altered cell-mediated immunity and sepsis, and interleukin 2 may have a role in limiting the adverse effects of sepsis.
Related Concept Videos
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease III: Crohn's Disease

